论文部分内容阅读
肾上腺素能受体阻断剂的出现,无论从治疗或阐明高血压病的发病机制方面,都开拓了一个新的研究领域。目前,肾上腺素能β受体阻断剂(以下简称β阻断剂)已广泛应用于高血压病的治疗。有些国家视为第一线药物,有的医院作为首选药物。此类药物不引起体位性低血压反应。心得安对β_1及β_2受体没有选择性阻断作用,禁用于支气管哮喘或呼吸道阻力增高的病人。心得宁虽然具有较好的心脏(β_1)选择作用,对高血压病有较好的疗效,但自1974年发现它能引起可怕的眼、皮肤、粘膜综合征,甚至发生死亡,因而西德、日本等国均已弃
Adrenergic receptor blockers appear, whether in the treatment or clarify the pathogenesis of hypertension, have opened up a new field of research. At present, adrenergic beta blockers (hereinafter referred to as beta blockers) have been widely used in the treatment of hypertension. Some countries regard first-line drugs and some hospitals as their preferred drug. Such drugs do not cause orthostatic hypotensive reactions. Propranolol does not have a selective blocking effect on beta 1 and beta 2 receptors and is prohibited in patients with bronchial asthma or increased airway resistance. Although it has better heart (β_1) choice, it has better curative effect on hypertension, but since 1974 it can cause terrible eye, skin, mucosal syndrome and even death, so West Germany, Japan and other countries have been abandoned